MedTrace Logo

Evaluation of Periodontal Status and hsCRP Levels in Females With PCOS on CPA/EE Combination Drug Regimen

NCT05021861 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2021-11-15

No results posted yet for this study

Summary

PCOS is a widely reported condition among young female population and anti-androgen agents are increasingly being used as part of the medical management of such cases. However, Clinical studies have reported higher prevalence of gingival inflammation, loss of attachment and gingival enlargement in women taking hormone based oral contraceptives. Additionally, CPA has been reported to have an osteoclastic action. Therefore, it is necessary to explore whether these medications affect the periodontal condition of PCOS patients, who already are pre-disposed to systemic inflammation. Therefore, the present study aims to evaluate the periodontal status of female patients diagnosed with Polycystic Ovary syndrome on Cyproterone acetate/ethinyl estradiol combination regimen.

Conditions

  • Periodontitis
  • Polycystic Ovary Syndrome
  • Gingivitis

Interventions

DRUG

Cyproterone Acetate, Ethinyl Estradiol Drug Combination

FEMALE PATIENTS WITH PCOS ON CPA/EE DRUG REGIMEN FOR ATLEAST 6 MONTHS

DIAGNOSTIC_TEST

FEMALE PATIENTS WITH PCOS

FEMALE PATIENTS WITH PCOS( NEWLY DIAGNOSED) ,NOT ON ANY MEDICATION,

DIAGNOSTIC_TEST

Control group

SYSTEMICALLY HEALTHY FEMALES

Sponsors & Collaborators

  • Postgraduate Institute of Dental Sciences Rohtak

    lead OTHER

Principal Investigators

  • RIDHIMA SINGHAL · PGIDS,ROHTAK

Eligibility

Min Age
15 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-30
Primary Completion
2022-07-31
Completion
2022-09-30

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05021861 on ClinicalTrials.gov